The group’s current projects centre around the ease of molecular-clinical correlative studies in the Vall d'Hebron Institute of Oncology. It provides orientation for oncology doctors and cancer biologists during the development, validation and interpretation of "omics" tests with direct clinical application. It is also developing and maintaining molecular/clinical databases, a resource for the institute’s medical oncologists, molecular pathologists and translational researchers. One example is the maintenance of the Gene Drug Knowledge Database (GDKD) (doi: 10.7303 / syn2370773), a structured database that uses standardised terminology to describe the associations of different annotations: types of tumours, genes, variants, response/resistance patterns to approved and experimental agents under clinical research and their respective PubMed identifiers.

It is working to promote research activities in collaboration with computational oncology scientists, focusing on predictive modelling and prognosis, the identification of “cancer drivers” and their potential to turn into solid tumours.

Visit the research group’s page


Subscribe to our newsletters and be a part of Vall d'Hebron Campus

Select the newsletter you want to receive:

By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Vall d’Hebron University Hospital Foundation – Research Institute.
Purpose: Manage the user’s contact information.
Legitimisation: Express acceptance of the privacy policy.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.